Sotorasib for advanced non-small cell lung cancer
0 Views
administrator
07/14/23
Prof Fabrice Barlesi speaks to ecancer about the ESMO 2020 virtual congress concerning sotorasib for non-small cell lung cancer (NSCLC).
The patients involved had solid tumours harbouring KRAS p.G12C mutations.
Prof Barlesi explains the adverse events, efficacy, and future prospects for the drug.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
-
Category
Show more
Facebook Comments
No comments found